TCTC Holdings LLC Reduces Stock Holdings in Pfizer Inc. $PFE

TCTC Holdings LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,253,887 shares of the biopharmaceutical company’s stock after selling 54,872 shares during the quarter. Pfizer comprises about 0.9% of TCTC Holdings LLC’s holdings, making the stock its 22nd biggest holding. TCTC Holdings LLC’s holdings in Pfizer were worth $31,949,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Curio Wealth LLC grew its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the 2nd quarter valued at about $29,000. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in Pfizer during the 2nd quarter worth approximately $30,000. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.4%

PFE stock opened at $27.58 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a fifty day moving average of $25.81 and a 200-day moving average of $25.19. The stock has a market capitalization of $156.78 billion, a PE ratio of 20.28 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The firm’s revenue was down 1.2% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.